Tafen Novolizer

The inhalation agent Tafen novolizer is an anti-asthmatic medication and is available in the form of a dosed powder mass.

Indications Tafena novolizer

Tafen novolizer is prescribed as part of complex treatment for patients with bronchial asthma or chronic pulmonary obstruction.

Acute bronchospasm is not an indication for the use of Tafen novolizer.

Release form

The cardboard package contains one inhaler device and a replaceable cartridge with 2.18 g of powder mass, which corresponds to 200 doses of 200 mcg of the active ingredient budesonide.

The white powdery mass is an inhalation agent from the glucocorticoid category – Tafen novolizer.

Pharmacodynamics

The inhalation agent Tafen novolizer belongs to the category of synthetic glucocorticoid drugs with a powerful external anti-inflammatory property and insignificant systemic penetration. When inhaled through the oral cavity, Tafen novolizer demonstrates an anti-inflammatory effect on the mucous tissues of the bronchi.

The active ingredient of Tafen novolizer - budesonide - deactivates various cellular structures involved in the development of the inflammatory reaction. Such structures include eosinophils, lymphocytes, neutrophils, macrophages, etc. Among the additional actions of the drug, it is especially worth highlighting the inhibition of the release of inflammatory mediators: this property allows you to restore respiratory function and reduce excessive bronchial reactivity.

The use of the drug Tafen novolizer in standard dosages is practically not accompanied by a resorptive effect. Tafen novolizer does not have mineralocorticoid activity and is well accepted by patients (even with prolonged therapy).

[ 1 ]

Pharmacokinetics

The main substance of Tafen novolizer is budesonide, which is a type of epimeric mixture (epimer 22R and epimer 22S - 1:1).

When Tafen Novolizer is inhaled, approximately a quarter of the administered volume is found in the lungs. The remaining amount of the drug settles in the tissues of the oral cavity, trachea and larynx, and also enters the digestive system.

The overall bioavailability of budesonide is low because about 90% of the component that reaches the bloodstream is inactivated in the liver. The maximum possible serum concentration can be reached in about half an hour after inhalation administration.

Tafen novolizer is easily distributed in the body and forms bonds with plasma albumins by 85%. The activity of glucocorticosteroids in the form of metabolites is less than 1% of the main substance of Tafen novolizer.

Metabolic products are excreted mainly through the renal filtration system and intestines. The half-life can be from 2 to 3 hours, and in childhood - up to one and a half hours.

[ 2 ]

Dosing and administration

Tafen novolizer is an inhalation product. One dose of the medication contains 200 mcg of the active ingredient and corresponds to one spray.

The amount of medication prescribed is determined individually. The average amount of medication can be from 200 to 1600 mcg of active ingredient per day. The maintenance dosage should correspond to the smallest effective amount of medication.

The standard dosage is one dose of the substance 1-2 times a day for patients aged 12 years and over.

If the daily amount of Tafen novolizer exceeds 4 doses, they should be administered 3-4 times.

The maximum daily dose of Tafen Novolizer is eight doses.

In childhood – from 6 to 12 years – it is recommended to use one dose 1-2 times a day. In this case, the maximum amount of the medicine can be 4 doses.

Treatment with medication may be long-term.

Before using the Tafen novolizer, you need to put the inhaler in a horizontal position, remove the protection in the form of a special cap, and then press the red button until it stops. During the last action, a click should occur, and the control indicator at the bottom of the inhaler should change color from red to green: the device is ready for use.

The patient should exhale deeply from the lungs, then bring the nozzle to the oral cavity and take a quick and deep breath. If the inhalation is done correctly, another click will sound, and the indicator will change color to red again.

After inhaling, the patient should hold his breath for a while and exhale slowly.

The device is equipped with a dosing counter, which indicates the remaining doses in the container. If the counter shows the number 0, it means that it is time to change the cartridge.

With prolonged use, the inhaler will require periodic cleaning. To do this, follow these steps:

• remove the protective cap, remove the mouthpiece;
• turn the inhaler upside down and remove the dosing mechanism;
• carefully pour the powder mass out of the inhaler, wipe the parts of the device well with a napkin;
• put the dosing mechanism back in place and put the cap back on.

It is strictly forbidden to wash the device with water or detergents.

[ 3 ], [ 4 ]

Use Tafena novolizer during pregnancy

The use of the inhalation agent Tafen novolizer by pregnant and lactating patients is highly undesirable. If possible, the agent should be replaced with another, safer one - both for the woman and for the child.

Contraindications

The inhalation agent Tafen novolizer should not be prescribed if you are prone to allergies to the drug, as well as in case of untreated fungal, bacterial or viral infectious diseases of the respiratory system.

Tafen novolizer is contraindicated in individuals with active pulmonary tuberculosis and in children under six years of age.

Side effects Tafena novolizer

Undesirable side effects during therapy with Tafen novolizer are not detected very often and quickly disappear on their own.

The following may be observed:

• sore throat, voice problems, cough;
• fungal infections of the oral mucosa;
• allergic reactions;
• feeling of anxiety, behavioral changes, depressive states.

In some patients, bronchospasm and hypercorticism associated with increased function of the adrenal cortex were observed.

Overdose

There have been no cases of acute overdose with Tafen novolizer to date. It is assumed that with prolonged use of the drug, signs of hypercorticism with suppression of the functionality of the adrenal cortex may occur. If this occurs, then the amount of Tafen novolizer should be gradually reduced to the minimum therapeutic dosage, and symptomatic treatment should be carried out simultaneously.

[ 5 ]

Interactions with other drugs

It is not advisable to carry out simultaneous treatment with Tafen novolizer and systemic glucocorticoids, as this increases the risk of developing undesirable side effects.

Preliminary inhalation administration of β2 _- adrenomimetic drugs promotes expansion of the bronchial lumen, facilitates the entry of Tafen novolizer into the respiratory organs and enhances its effect.

Since metabolic processes involving the active ingredient budesonide occur with the participation of cytochrome P ₄₅₀ -3A, it is recommended to avoid the simultaneous use of such medications as ketoconazole, oleandomycin, cyclosporine or ethinyl estradiol: combining Tafen novolizer with the listed medications may lead to an increase in the serum content of budesonide.

[ 6 ]

Storage conditions

It is recommended to store packages with Tafen novolizer in dry places, inaccessible to children. The optimal temperature for preserving the drug is from +18 to +30°C.

Shelf life

Undamaged packaging with Tafen novolizer can be stored for up to three years.

The cartridge for the drug can be stored for up to 3 months after opening.

The Tafen Novolizer inhaler can be stored for one year after first use.

[ 7 ]